ClinicalTrials.gg
RecruitingNCT07478380Updated Mar 17, 2026

Transcutaneous pO₂ Monitoring in PICU

An observational study in Pediatric Critical Illness, sponsored by Istanbul Medeniyet University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Istanbul Medeniyet University · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
1 Month to 18 Years
Sex
All
01

Study summary

Arterial blood gas analysis is commonly used in pediatric intensive care units (PICUs) to assess oxygen and carbon dioxide levels in critically ill children. However, arterial blood sampling is invasive, can be painful, and may need to be repeated frequently. Transcutaneous monitoring provides a noninvasive method to continuously measure oxygen (pO₂) and carbon dioxide (pCO₂) levels through the skin, but its accuracy in critically ill pediatric patients requires further evaluation.

The purpose of this observational study is to compare transcutaneous pO₂ and pCO₂ measurements with arterial blood gas values in pediatric intensive care unit patients. By analyzing paired measurements obtained simultaneously during routine clinical care, this study aims to evaluate the agreement between transcutaneous and arterial measurements, with a particular focus on whether transcutaneous pO₂ can serve as a reliable alternative to arterial sampling.

The results of this study may help clarify the role of transcutaneous monitoring in pediatric intensive care and may contribute to reducing the need for invasive blood sampling in selected patients.

Read the detailed description

Detailed Description

Arterial blood gas (ABG) analysis is the gold standard for assessing oxygenation and ventilation in critically ill children admitted to the pediatric intensive care unit (PICU). Despite its clinical value, ABG sampling is invasive, may cause discomfort, and often requires repeated blood draws. Transcutaneous monitoring offers a noninvasive, continuous method for estimating partial pressures of oxygen (pO₂) and carbon dioxide (pCO₂) through the skin. However, the accuracy and clinical reliability of transcutaneous measurements in critically ill pediatric patients remain variable and require further evaluation.

This observational cohort study aims to assess the agreement between transcutaneous pO₂ (Tc pO₂) and pCO₂ (Tc pCO₂) measurements and corresponding arterial blood gas values (PaO₂ and PaCO₂) in pediatric patients admitted to the PICU. Eligible patients are those who undergo arterial blood gas sampling and concurrent transcutaneous monitoring as part of routine clinical care. Paired measurements will be obtained simultaneously to minimize temporal variability and ensure comparability.

The primary outcome of the study is the agreement between Tc pO₂ and PaO₂ measurements. Secondary analyses will evaluate the agreement between Tc pCO₂ and PaCO₂ values. Agreement will be assessed using appropriate statistical methods, including correlation analysis and Bland-Altman analysis, to determine bias and limits of agreement between measurement techniques.

By evaluating the performance of transcutaneous monitoring in a real-world PICU setting, this study seeks to determine whether Tc pO₂ can be considered a reliable alternative to arterial oxygen measurements in selected pediatric patients. The findings may support the integration of noninvasive monitoring strategies into clinical practice and potentially reduce the frequency of invasive arterial blood sampling in pediatric intensive care.

02

Conditions studied

  • Pediatric Critical Illness

Keywords

  • Pediatric Intensive Care Unit
  • Transcutaneous Monitoring
  • Arterial Blood Gas
  • Noninvasive Monitoring
03

In context

Lead sponsor

Istanbul Medeniyet University is the lead sponsor of 193 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will include pediatric patients aged 1 month to 18 years admitted to the Pediatric Intensive Care Unit (PICU) who undergo arterial blood gas analysis and concurrent transcutaneous pCO₂ and pO₂ monitoring as part of routine clinical care. Patients with an indwelling arterial catheter and adequate peripheral perfusion allowing reliable transcutaneous measurements will be eligible. The study population represents critically ill children requiring close respiratory and hemodynamic monitoring in the PICU setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Eligibility Criteria

Inclusion criteria

Inclusion Criteria:

  • Age between 1 month and 18 years
  • Admission to the Pediatric Intensive Care Unit (PICU)
  • Presence of an arterial catheter allowing arterial blood gas (ABG) sampling
  • Simultaneous or paired transcutaneous pCO₂ and pO₂ monitoring available
  • Hemodynamically stable at the time of measurement

Exclusion criteria

Exclusion Criteria:

  • Severe skin disease, burns, or local skin infection at the transcutaneous sensor site
  • Severe peripheral perfusion impairment (e.g., shock or high-dose vasopressor support)
  • Congenital or acquired conditions interfering with accurate transcutaneous measurements
  • Technical failure or inability to obtain reliable transcutaneous readings
  • Missing or incomplete paired ABG-transcutaneous measurement data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Agreement Between Transcutaneous pO₂ and Arterial pO₂

    Agreement between transcutaneous oxygen partial pressure (Tc pO₂) and arterial oxygen partial pressure (PaO₂) obtained from arterial blood gas analysis in pediatric intensive care unit patients.

    Time frame: At the time of each paired transcutaneous monitoring and arterial blood gas measurement during PICU admission (up to 28 days)

Secondary outcomes

  1. Agreement Between Transcutaneous pCO₂ and Arterial pCO₂

    Agreement between transcutaneous carbon dioxide partial pressure (Tc pCO₂) and arterial carbon dioxide partial pressure (PaCO₂) obtained from arterial blood gas analysis in pediatric intensive care unit patients.

    Time frame: At the time of each paired transcutaneous monitoring and arterial blood gas measurement during PICU admission (up to 28 days)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 17, 2026
StartActual
Mar 10, 2026
Primary completionEst.
Sep 1, 2026
CompletionEst.
Oct 10, 2026
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07478380
Responsible party
Ayse Asik (Pediatric Critical Care Fellow, Department of Pediatrics, Istanbul Medeniyet University) — Principal investigator
First posted
Mar 17, 2026
Start date
Mar 10, 2026
Primary completion
Sep 1, 2026 (estimated)
Completion
Oct 10, 2026 (estimated)
Last update
Mar 17, 2026

Study contacts

Ayşe Aşık, MD
Contact
drayseasik@gmail.com
+905533280449

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion